Recent Drake Center Outcomes
Meaningful improvement.
Measured in our own patients.
Results from patients completing our current six-treatment program in 2024–2025, with paired PHQ-9 measurements.
67%Remission
Among recent six-treatment program completers with paired PHQ-9 data.
83%Clinical response
At least a 50% reduction in depression symptoms, measured by PHQ-9.
12pointsAverage PHQ-9 improvement
Average PHQ-9 improved from approximately 17 before treatment to 5 after treatment.
Recent results are based on Drake Center patients completing the six-treatment course in 2024–2025 who had paired PHQ-9 measurements. Clinical response is defined as a reduction of at least 50% in PHQ-9 score; remission is defined as PHQ-9 ≤4. Individual outcomes vary.
Our broader five-year experienceImprovement builds early.
Across 265 patients and 1,433 treatments through September 15, 2026, most improvement builds rapidly during the first 3–4 treatments.
77% clinical response by treatment 4.
Approximately 11-point average PHQ-9 reduction by treatment 4.
47% remission by treatment 5 among patients beginning with clinically significant depression.
Figures reflect patients with available measurements at the specified treatment points.
A focused course of care
79% of six-treatment completers had no booster treatment recorded at The Drake Center 60 or more days later. Patients who returned for boosters typically received 2 boosters.
Absence of a recorded booster does not prove continued remission or indicate what care a patient may have received elsewhere.